Atara Biotherapeutics (ATRA) Total Current Liabilities (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Total Current Liabilities for 14 consecutive years, with $6.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 52.98% year-over-year to $6.8 million; the trailing twelve-month figure through Jun 2026 stood at $6.8 million (down 52.98% YoY), and the FY2025 full-year result was $14.9 million, down 88.91% from the prior year.
• Total Current Liabilities improved to $6.8 million in Q2 2026 per ATRA's latest filing, from $5.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $180.7 million in Q1 2024 and bottomed at $5.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $78.3 million across 5 years, with a median of $73.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 166.21% in 2024, then slumped 90.18% in 2025.
• Over 5 years, Total Current Liabilities stood at $78.9 million in 2022, then soared by 80.22% to $142.2 million in 2023, then fell by 5.38% to $134.6 million in 2024, then tumbled by 88.91% to $14.9 million in 2025, then sank by 54.11% to $6.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $6.8 million, $5.6 million, and $14.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.